Cargando…
Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro
INTRODUCTION: Cancer chemotherapy faces two major challenges – high toxicity of active substances and tumor resistance to drugs. Low toxic nanocarriers in combination with anticancer agents can significantly increase the effectiveness of therapy. Modern advances in nanotechnology make it easy to cre...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473965/ https://www.ncbi.nlm.nih.gov/pubmed/37662686 http://dx.doi.org/10.2147/IJN.S416046 |
_version_ | 1785100388609818624 |
---|---|
author | Chumachenko, Vasyl Virych, Pavlo Nie, Guochao Virych, Petro Yeshchenko, Oleg Khort, Pavlo Tkachenko, Anton Prokopiuk, Volodymyr Lukianova, Nataliia Zadvornyi, Taras Rawiso, Michel Ding, Liyao Kutsevol, Nataliya |
author_facet | Chumachenko, Vasyl Virych, Pavlo Nie, Guochao Virych, Petro Yeshchenko, Oleg Khort, Pavlo Tkachenko, Anton Prokopiuk, Volodymyr Lukianova, Nataliia Zadvornyi, Taras Rawiso, Michel Ding, Liyao Kutsevol, Nataliya |
author_sort | Chumachenko, Vasyl |
collection | PubMed |
description | INTRODUCTION: Cancer chemotherapy faces two major challenges – high toxicity of active substances and tumor resistance to drugs. Low toxic nanocarriers in combination with anticancer agents can significantly increase the effectiveness of therapy. Modern advances in nanotechnology make it easy to create materials with the necessary physical and chemical properties. METHODS: Two hybrid nanosystems of dextran-polyacrylamide/ zinc oxide nanoparticles (D-PAA/ZnO NPs) were synthesized in aqueous solution with zinc sulphate (D-PAA/ZnO NPs (SO(4)(2-))) and zinc acetate (D-PAA/ZnO NPs (-OAc)). The light absorption, fluorescence, dynamic light scattering and transmission electron microscopy for nanocomposite characterization were used. MTT, neutral red uptake and scratch assays were selected as fibroblasts cytotoxicity assays. Cytotoxicity was tested in vitro for normal fibroblasts, MAEC, prostate (LNCaP, PC-3, DU-145) and breast (MDA-MB-231, MCF-7) cancer cells lines. Immunocytochemical methods were used for detection of Ki-67, p53, Bcl-2, Bax, e-cadherin, N-cadherin and CD44 expression. Acridine orange was used to detect morphological changes in cells. RESULTS: The radius of ZnO NPs (SO(4)(2-)) was 1.5 nm and ZnO NPs (-OAc) was 2 nm. The nanosystems were low-toxic to fibroblasts, MAEC. Cells in the last stages of apoptosis with the formation of apoptotic bodies were detected for all investigated cancer cell lines. Proapoptotic proteins expression in cancer cells indicates an apoptotic death. Increased expression of E-cadherin and N-cadherin was registered for cancer cells line LNCaP, PC-3, DU-145 and MCF-7 after 48 h incubation with D-PAA/ZnO NPs (SO(4)(2-)). CONCLUSION: The nanosystems were low-toxic to fibroblasts, MAEC. The D-PAA/ZnO NPs nanosystem synthesized using zinc sulphate demonstrates high cytotoxicity due to destruction of various types of cancer cells in vitro and potentially increases adhesion between cells. Thus, our findings indicate the selective cytotoxicity of D-PAA/ZnO NPs against cancer cells and can be potentially used for cancer treatment. |
format | Online Article Text |
id | pubmed-10473965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104739652023-09-03 Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro Chumachenko, Vasyl Virych, Pavlo Nie, Guochao Virych, Petro Yeshchenko, Oleg Khort, Pavlo Tkachenko, Anton Prokopiuk, Volodymyr Lukianova, Nataliia Zadvornyi, Taras Rawiso, Michel Ding, Liyao Kutsevol, Nataliya Int J Nanomedicine Original Research INTRODUCTION: Cancer chemotherapy faces two major challenges – high toxicity of active substances and tumor resistance to drugs. Low toxic nanocarriers in combination with anticancer agents can significantly increase the effectiveness of therapy. Modern advances in nanotechnology make it easy to create materials with the necessary physical and chemical properties. METHODS: Two hybrid nanosystems of dextran-polyacrylamide/ zinc oxide nanoparticles (D-PAA/ZnO NPs) were synthesized in aqueous solution with zinc sulphate (D-PAA/ZnO NPs (SO(4)(2-))) and zinc acetate (D-PAA/ZnO NPs (-OAc)). The light absorption, fluorescence, dynamic light scattering and transmission electron microscopy for nanocomposite characterization were used. MTT, neutral red uptake and scratch assays were selected as fibroblasts cytotoxicity assays. Cytotoxicity was tested in vitro for normal fibroblasts, MAEC, prostate (LNCaP, PC-3, DU-145) and breast (MDA-MB-231, MCF-7) cancer cells lines. Immunocytochemical methods were used for detection of Ki-67, p53, Bcl-2, Bax, e-cadherin, N-cadherin and CD44 expression. Acridine orange was used to detect morphological changes in cells. RESULTS: The radius of ZnO NPs (SO(4)(2-)) was 1.5 nm and ZnO NPs (-OAc) was 2 nm. The nanosystems were low-toxic to fibroblasts, MAEC. Cells in the last stages of apoptosis with the formation of apoptotic bodies were detected for all investigated cancer cell lines. Proapoptotic proteins expression in cancer cells indicates an apoptotic death. Increased expression of E-cadherin and N-cadherin was registered for cancer cells line LNCaP, PC-3, DU-145 and MCF-7 after 48 h incubation with D-PAA/ZnO NPs (SO(4)(2-)). CONCLUSION: The nanosystems were low-toxic to fibroblasts, MAEC. The D-PAA/ZnO NPs nanosystem synthesized using zinc sulphate demonstrates high cytotoxicity due to destruction of various types of cancer cells in vitro and potentially increases adhesion between cells. Thus, our findings indicate the selective cytotoxicity of D-PAA/ZnO NPs against cancer cells and can be potentially used for cancer treatment. Dove 2023-08-28 /pmc/articles/PMC10473965/ /pubmed/37662686 http://dx.doi.org/10.2147/IJN.S416046 Text en © 2023 Chumachenko et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Chumachenko, Vasyl Virych, Pavlo Nie, Guochao Virych, Petro Yeshchenko, Oleg Khort, Pavlo Tkachenko, Anton Prokopiuk, Volodymyr Lukianova, Nataliia Zadvornyi, Taras Rawiso, Michel Ding, Liyao Kutsevol, Nataliya Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro |
title | Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro |
title_full | Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro |
title_fullStr | Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro |
title_full_unstemmed | Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro |
title_short | Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro |
title_sort | combined dextran-graft-polyacrylamide/zinc oxide nanocarrier for effective anticancer therapy in vitro |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473965/ https://www.ncbi.nlm.nih.gov/pubmed/37662686 http://dx.doi.org/10.2147/IJN.S416046 |
work_keys_str_mv | AT chumachenkovasyl combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT virychpavlo combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT nieguochao combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT virychpetro combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT yeshchenkooleg combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT khortpavlo combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT tkachenkoanton combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT prokopiukvolodymyr combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT lukianovanataliia combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT zadvornyitaras combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT rawisomichel combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT dingliyao combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro AT kutsevolnataliya combineddextrangraftpolyacrylamidezincoxidenanocarrierforeffectiveanticancertherapyinvitro |